Search results for: Jae-Lyun Lee

Items from 1 to 20 out of 116 results

article

Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial

Sun Young Rha, Toni K. Choueiri, Vsevolod B. Matveev, Anna Alyasova, more

International Journal of Cancer > 153 > 6 > 1241 - 1250

In the CLEAR trial, lenvatinib plus pembrolizumab met study endpoints of superiority vs sunitinib in the first‐line treatment of patients with advanced renal cell carcinoma. We report the efficacy and safety results of the East Asian subset (ie, patients in Japan and the Republic of Korea) from the CLEAR trial. Of 1069 patients randomly assigned to receive either lenvatinib plus pembrolizumab, lenvatinib...

article

Clinical evidence and insights supporting the use of avelumab first‐line maintenance treatment in patients with advanced urothelial carcinoma in the Asia‐Pacific region

Masatoshi Eto, Jae‐Lyun Lee, Yen‐Hwa Chang, Seasea Gao, more

Asia‐Pacific Journal of Clinical Oncology > 18 > 5 > e191 - e203

Until recently, international and Asia‐specific guidelines for advanced urothelial carcinoma (UC) recommended first‐line (1L) platinum‐based chemotherapy, followed by second‐line (2L) anti‐PD‐1 or anti‐PD‐L1 immune checkpoint inhibitor (ICI) therapy where possible, or 1L ICI therapy in cisplatin‐ineligible patients with PD‐L1+ tumors. However, long‐term outcomes remain poor and only a minority of...

article

Clinical course of patients with renal cell carcinoma or urothelial carcinoma who had stable disease as an initial response to a PD‐1 or PD‐L1 inhibitor

Inhwan Hwang, Inkeun Park, Shin‐Kyo Yoon, Jae Lyun Lee

Asia‐Pacific Journal of Clinical Oncology > 18 > 4 > 371 - 377

Background About 17%–34% of patients with non‐prostatic genitourinary (GU) cancer had stable disease (SD) as their best response to programmed cell death protein 1/programmed death‐ligand 1 (PD‐1/PD‐L1) inhibitors. However, most efficacy studies of PD‐1/PD‐L1 inhibitors are focused on the response and its durability. Little is known about patients' clinical outcomes with SD as their initial response...

article

Exposure‐response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy

Ronald Wit, Thomas Powles, Daniel Castellano, Andrea Necchi, more

British Journal of Clinical Pharmacology > 88 > 7 > 3182 - 3192

Aims Patients with advanced urothelial carcinoma (UC) who progress after platinum‐based chemotherapy have a poor prognosis, and there is a medical need to improve current treatment options. Ramucirumab plus docetaxel significantly improved progression‐free survival but not overall survival (OS) in platinum‐refractory advanced UC (RANGE trial; NCT02426125). Here, we report the exposure‐response (ER)...

article

Clinical features and oncological outcomes of primary female urethral cancer

Wonchul Lee, Jesang Yu, Jae‐Lyun Lee, Young Seok Kim, more

Journal of Surgical Oncology > 125 > 5 > 907 - 915

Purpose Investigation of the clinical features and treatment outcomes of primary female urethral cancer (FUC) at a single institution. Materials and Methods We retrospectively reviewed 32 FUC patients during 1997–2017. We investigated preoperative risk factors predicting overall (overall survival [OS]) and recurrence‐free survival (RFS) and reviewed clinical features, treatment modality, and oncologic...

article

Radium‐223 in Asian patients with castration‐resistant prostate cancer with symptomatic bone metastases: A single‐arm phase 3 study

Tie Zhou, Fangjian Zhou, Jianming Guo, Hongcheng Shi, more

Asia‐Pacific Journal of Clinical Oncology > 17 > 6 > 462 - 470

Aim Radium‐223, a targeted alpha therapy, is approved widely for the treatment of patients with metastatic castrate‐resistant prostate cancer, based on a pivotal phase 3 study in predominantly white patients. We investigated the efficacy and safety of radium‐223 in Asian patients with castrate‐resistant prostate cancer and metastatic bone disease. Methods This multicenter, prospective, single‐arm,...

article

Optimal pathological response after neoadjuvant chemotherapy for muscle‐invasive bladder cancer: results from a global, multicentre collaboration

Praful Ravi, Gregory R. Pond, Leonidas N. Diamantopoulos, Christopher Su, more

BJU International > 128 > 5 > 607 - 614

Objectives To evaluate outcomes of patients achieving a post‐treatment pathological stage of <ypT2N0 at radical cystectomy (RC) following neoadjuvant chemotherapy (NAC) for muscle‐invasive bladder cancer (MIBC) to identify an optimal definition of pathological response. Patients and Methods Patients from 10 international centres who underwent NAC for cT2–4aN0–1 MIBC and achieved <ypT2N0 disease...

article

FGFR1 is associated with c‐MYC and proangiogenic molecules in metastatic renal cell carcinoma under anti‐angiogenic therapy

Jee Young Park, Pil‐Jong Kim, Su‐Jin Shin, Jae‐Lyun Lee, more

Histopathology > 76 > 6 > 838 - 851

Aims This study aimed to investigate the clinicopathological significance of FGFR1 and c‐MYC expression, particularly in relation to angiogenesis in clear cell renal cell carcinoma (CCRCC). Methods and results Immunohistochemistry and fluorescence in‐situ hybridisation were conducted with tissue microarrays from 91 metastatic CCRCC patients who received VEGF receptor tyrosine kinase inhibitors...

article

A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component

Inkeun Park, Hyo Jin Lee, Woo Kyoon Bae, Shinkyo Yoon, more

Investigational New Drugs > 2019 > 37 > 6 > 1239-1246

Summary Introduction We conducted a multicenter, phase 2 trial using gemcitabine plus axitinib (GX) in patients with recurrent or metastatic sarcomatoid renal cell carcinoma (SRCC) to evaluate its efficacy and safety. Methods Patients with advanced RCC and a sarcomatoid component of ≥25% on resected kidney or exclusive sarcomatoid carcinoma on needle biopsy were included. Patients received gemcitabine...

article

Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failures

Inkeun Park, Young Sup Shim, Heounjeong Go, Bum Sik Hong, more

BMC Urology > 2019 > 19 > 1 > 1-5

Background Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is a rare hereditary kidney cancer syndrome in which affected individuals are at risk of skin and uterine leiomyomatosis and kidney cancer. HLRCC-associated kidney cancer is a lethal disease with a highly aggressive behavior, and there is no standard treatment option for metastatic disease. Case presentation Here, we report a...

article

3′-Deoxy-3’-¹⁸F-Fluorothymidine and ¹⁸F-Fluorodeoxyglucose positron emission tomography for the early prediction of response to Regorafenib in patients with metastatic colorectal cancer refractory to all standard therapies

Jeong Eun Kim, Sun Young Chae, Jwa Hoon Kim, Hwa Jung Kim, more

European Journal of Nuclear Medicine and Molecular Imaging > 2019 > 46 > 8 > 1713-1722

Purpose The purpose of this study was to evaluate the value of 3′-deoxy-3′-¹⁸F-fluorothymidine (¹⁸F-FLT) and ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) positron emission tomography/computed tomography (PET/CT) for early prediction of standard anatomic response and survival outcomes in patients with metastatic colorectal cancer (mCRC) receiving Regorafenib. Methods Sixty-eight patients with mCRC refractory...

article

Genomics of drug sensitivity in bladder cancer: an integrated resource for pharmacogenomic analysis in bladder cancer

Adnan Ahmad Ansari, Inkeun Park, Inki Kim, Sojung Park, more

BMC Medical Genomics > 2018 > 11 > 1 > 1-8

Background Bladder cancer has numerous genomic features that are potentially actionable by targeted agents. Nevertheless, both pre-clinical and clinical research using molecular targeted agents have been very limited in bladder cancer. Results We created the Genomics of Drug Sensitivity in Bladder Cancer (GDBC) database, an integrated database (DB) to facilitate the genomic understanding of bladder...

article

Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy

Guru Sonpavde, Gregory Russell Pond, Jonathan E. Rosenberg, Toni K. Choueiri, more

Clinical Genitourinary Cancer > 2018 > 16 > 4 > e961-e967

Optimal end points in phase 2 trials evaluating salvage therapy for metastatic urothelial carcinoma are necessary to identify promising drugs, particularly immunotherapeutics, where response and progression-free survival may be unreliable. We developed a nomogram using data from phase 2 trials of historical agents to estimate the 12-month overall survival (OS) for patients to which observed survival...

article

Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial

Jun Guo, Jie Jin, Mototsugu Oya, Hirotsugu Uemura, more

Journal of Hematology & Oncology > 2018 > 11 > 1 > 1-10

Background The international, phase 3 COMPARZ study demonstrated that pazopanib and sunitinib have comparable efficacy as first-line therapy in patients with advanced renal cell carcinoma, but that safety and quality-of-life profiles favor pazopanib. Our report analyzed pazopanib and sunitinib safety in Asian and non-Asian subpopulations. Methods Patients were randomized 1:1 to receive pazopanib...

article

Stereotactic body-radiotherapy boost dose of 18 Gy vs 21 Gy in combination with androgen-deprivation therapy and whole-pelvic radiotherapy for intermediate- or high-risk prostate cancer: a study protocol for a randomized controlled, pilot trial

Yeon Joo Kim, Hanjong Ahn, Choung-Soo Kim, Jae-Lyun Lee, more

Trials > 2018 > 19 > 1 > 1-6

Background Combination therapy using external-beam radiotherapy (EBRT) with a brachytherapy boost has demonstrated superior biochemical control than dose-escalated EBRT alone. Whereas brachytherapy is disadvantageous because it is an invasive procedure, stereotactic body-radiotherapy (SBRT) using CyberKnife could emulate the dose distribution of brachytherapy and is a non-invasive and safe modality...

article

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Daniel P Petrylak, Ronald de Wit, Kim N Chi, Alexandra Drakaki, more

The Lancet > 2017 > 390 > 10109 > 2266-2277

Few treatments with a distinct mechanism of action are available for patients with platinum-refractory advanced or metastatic urothelial carcinoma. We assessed the efficacy and safety of treatment with docetaxel plus either ramucirumab—a human IgG1 VEGFR-2 antagonist—or placebo in this patient population. We did a randomised, double-blind, phase 3 trial in patients with advanced or metastatic urothelial...

article

Development of Response Classifier for Vascular Endothelial Growth Factor Receptor (VEGFR)-Tyrosine Kinase Inhibitor (TKI) in Metastatic Renal Cell Carcinoma

Heounjeong Go, Mun Jung Kang, Pil-Jong Kim, Jae-Lyun Lee, more

Pathology & Oncology Research > 2019 > 25 > 1 > 51-58

Vascular endothelial growth factor receptor (VEGFR)-targeted therapy improved the outcome of metastatic renal cell carcinoma (mRCC) patients. However, a prediction of the response to VEGFR-tyrosine kinase inhibitor (TKI) remains to be elucidated. We aimed to develop a classifier for VEGFR-TKI responsiveness in mRCC patients. Among 101 mRCC patients, ones with complete response, partial response, or...

article

Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing

Kyoungmin Lee, Changhoon Yoo, Kyu-pyo Kim, Kyoung-Jin Park, more

Investigational New Drugs > 2018 > 36 > 1 > 163-169

Summary Introduction Germline BRCA mutations may have therapeutic implications as surrogate markers of DNA-damage repair status in pancreatic ductal adenocarcinoma (PDAC). We performed a prospective study to evaluate the efficiency of risk criteria based on personal or family history of breast and ovarian cancer for determining germline BRCA mutations in PDAC patients with Asian ethnicity. Methods...

article

Second-line Chemotherapy in Older Patients With Metastatic Urothelial Carcinoma: Pooled Analysis of 10 Second-line Studies

Samer Salah, Jae-Lyun Lee, Antonio Rozzi, Hiroshi Kitamura, more

Clinical Genitourinary Cancer > 2017 > 15 > 4 > e563-e571

Older patients with metastatic urothelial carcinoma (UC) are under-represented in clinical trials, and data regarding outcomes for second-line therapy is limited.Individual data for patients with metastatic UC, aged ≥ 70 years, were pooled from 10 second-line studies. The influence of potential prognostic factors on overall survival (OS) was assessed via univariate and multivariate Cox regression...

article

Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma

Guillermo De Velasco, Wanling Xie, Frede Donskov, Laurence Albiges, more

Clinical Genitourinary Cancer > 2017 > 15 > 3 > 403-410.e2

A significant subgroup of metastatic renal cell carcinoma (mRCC) patients discontinue vascular endothelial growth factor-targeted therapies (VEGF-TT) because of toxicity. Whether clinical outcomes differ in patients who receive second-line (2L) targeted therapy on the basis of reason for discontinuation of first-line (1L) therapy is unknown.Patients from 15 International Metastatic Renal Cell Carcinoma...

Publication date

Last 3 years (6)

Close

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

From:

To:
Set your own date range

Keywords

Data set

Springer (68)
Elsevier (31)
Wiley (17)

Journal

Cancer Chemotherapy and Pharmacology (20)
Investigational New Drugs (14)
Clinical Genitourinary Cancer (8)
Supportive Care in Cancer (7)
European Urology (6)
Journal of Cancer Research and Clinical Oncology (6)
Asia‐Pacific Journal of Clinical Oncology (4)
Cancer Science (3)
European Journal of Cancer (3)
International Journal of Radiation Oncology, Biology, Physics (3)
The Journal of Urology (3)
The Lancet Oncology (3)
Annals of Surgical Oncology (2)
BMC Urology (2)
Biology of Blood and Marrow Transplantation (2)
Gastric Cancer (2)
Journal of Gastroenterology and Hepatology (2)
Journal of Surgical Oncology (2)
Medical Oncology (2)
Annals of Hematology (1)
Apoptosis (1)
BJU International (1)
BMC Medical Genomics (1)
British Journal of Clinical Pharmacology (1)
Cancer (1)
Digestive Diseases and Sciences (1)
European Journal of Nuclear Medicine and Molecular Imaging (1)
Hematological Oncology (1)
Histopathology (1)
International Journal of Cancer (1)
International Journal of Clinical Oncology (1)
Journal for ImmunoTherapy of Cancer (1)
Journal of Hematology & Oncology (1)
Journal of Neuro-Oncology (1)
Pathology & Oncology Research (1)
Surgery (1)
The Lancet (1)
Transfusion and Apheresis Science (1)
Trials (1)
Tumor Biology (1)
World Journal of Urology (1)
more

INFONA - science communication portal

Search results for: Jae-Lyun Lee

Efficacy and safety of lenvatinib plus pembrolizumab vs sunitinib in the East Asian subset of patients with advanced renal cell carcinoma from the CLEAR trial

Clinical evidence and insights supporting the use of avelumab first‐line maintenance treatment in patients with advanced urothelial carcinoma in the Asia‐Pacific region

Clinical course of patients with renal cell carcinoma or urothelial carcinoma who had stable disease as an initial response to a PD‐1 or PD‐L1 inhibitor

Exposure‐response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy

Clinical features and oncological outcomes of primary female urethral cancer

Radium‐223 in Asian patients with castration‐resistant prostate cancer with symptomatic bone metastases: A single‐arm phase 3 study

Optimal pathological response after neoadjuvant chemotherapy for muscle‐invasive bladder cancer: results from a global, multicentre collaboration

FGFR1 is associated with c‐MYC and proangiogenic molecules in metastatic renal cell carcinoma under anti‐angiogenic therapy

A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component

Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failures

3′-Deoxy-3’-¹⁸F-Fluorothymidine and ¹⁸F-Fluorodeoxyglucose positron emission tomography for the early prediction of response to Regorafenib in patients with metastatic colorectal cancer refractory to all standard therapies

Genomics of drug sensitivity in bladder cancer: an integrated resource for pharmacogenomic analysis in bladder cancer

Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy

Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial

Stereotactic body-radiotherapy boost dose of 18 Gy vs 21 Gy in combination with androgen-deprivation therapy and whole-pelvic radiotherapy for intermediate- or high-risk prostate cancer: a study protocol for a randomized controlled, pilot trial

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Development of Response Classifier for Vascular Endothelial Growth Factor Receptor (VEGFR)-Tyrosine Kinase Inhibitor (TKI) in Metastatic Renal Cell Carcinoma

Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing

Second-line Chemotherapy in Older Patients With Metastatic Urothelial Carcinoma: Pooled Analysis of 10 Second-line Studies

Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma

Filter options

Publication date

Keywords

Data set

Journal

INFONA - science communication portal

Search results for: Jae-Lyun Lee

Add recipient

Sending message cancelled

Are you sure you want to cancel sending this message?

Send message

Filter options

Publication date

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

Keywords

Data set

Journal

Reporting an error / abuse

Sending the report failed

Accessibility options